```html

Koay‑Bates Disease (Eosinophilic Gastroenteritis)

Overview

Koay‑Bates disease, more formally known as eosinophilic gastroenteritis (EGE), is a rare, chronic inflammatory condition in which a type of white blood cell called an eosinophil accumulates in the lining of the stomach and small intestine. The infiltration leads to inflammation, thickening of the gut wall, and a range of gastrointestinal (GI) symptoms.

• Prevalence: EGE is estimated to affect between 1 and 8 individuals per 100,000 people worldwide, making it considerably less common than eosinophilic esophagitis (Mayo Clinic).
• Age & gender: It can occur at any age but peaks in the 30‑50‑year range. Slight male predominance has been noted (≈55 % male).
• Geography: Cases are reported globally; higher detection rates are observed in North America and Europe, likely due to greater awareness and access to specialist testing.

Because its symptoms overlap with more common GI disorders (e.g., irritable bowel syndrome, Crohn’s disease), EGE is frequently under‑diagnosed or misdiagnosed, leading to delayed treatment.

Symptoms

The clinical picture depends on which layer of the gastrointestinal wall is involved—mucosal, muscular, or serosal. Below is a comprehensive list of reported manifestations:

Mucosal involvement (most common)

• Abdominal pain or cramping: Often vague, post‑prandial, and may improve with fasting.
• Nausea & vomiting: Can be intermittent or persistent; sometimes food‑related.
• Diarrhea: May be watery, occasionally with blood or mucus.
• Weight loss: Resulting from malabsorption or reduced intake due to pain.
• Steatorrhea (fatty stools): Sign of maldigestion.

Muscular involvement

• Persistent abdominal pain that may be less related to meals.
• Partial intestinal obstruction: Bloating, distention, and inability to pass gas or stool.
• Vomiting of undigested food (food‑level obstruction).

Serosal involvement

• Ascites: Fluid accumulation in the abdomen causing a feeling of fullness.
• Peripheral eosinophilia: Elevated eosinophil count in the blood (often >500 cells/µL).

Systemic or associated features

• Asthma or allergic rhinitis (present in up to 30 % of patients).
• Food allergies—especially to dairy, soy, wheat, or shellfish.
• Dermatologic findings such as eczema or urticaria.

Symptoms can be intermittent, and many patients experience “flare‑ups” that last weeks to months, interspersed with periods of relative remission.

Causes and Risk Factors

The exact etiology of EGE remains incompletely understood, but several mechanisms have been identified:

Immunologic factors

• Allergic hypersensitivity: 60–70 % of patients have a personal or family history of atopy (asthma, eczema, allergic rhinitis). IgE‑mediated responses to specific foods trigger eosinophil recruitment.
• Th2 cytokine milieu: Elevated interleukins 4, 5, 13 promote eosinophil growth and survival (NIH, JACI 2015).

Genetic predisposition

• Polymorphisms in genes regulating eosinophil trafficking (e.g., CCR3, IL5RA) have been linked to higher risk, although data are still emerging.

Environmental triggers

• Seasonal allergens, drug reactions (e.g., non‑steroidal anti‑inflammatory drugs), and infections can precipitate flare‑ups.

Risk factors

• Age 30–50 years, male sex, atopic background.
• History of food allergies or eosinophilic disorders elsewhere (eosinophilic esophagitis, asthma).
• Geographic areas with high prevalence of parasitic infections (though EGE is distinct from helminth‑induced eosinophilia).

Diagnosis

Because symptoms are nonspecific, a systematic approach is essential.

Step‑by‑step diagnostic algorithm

1. Clinical evaluation: Detailed history focusing on dietary triggers, atopic diseases, and symptom pattern.
2. Laboratory studies:
   • Complete blood count (CBC) – looking for peripheral eosinophilia.
   • Serum IgE level – often elevated.
   • Stool studies – to exclude infections, parasites, and occult blood.
3. Imaging: Abdominal ultrasound or CT scan may reveal wall thickening, ascites, or obstruction, but findings are not diagnostic.
4. Endoscopy with biopsies: The gold standard. Multiple biopsies from the stomach, duodenum, and, if indicated, jejunum are taken. Pathology shows >20–30 eosinophils per high‑power field (HPF) in the lamina propria or deeper layers.
5. Special tests (selected cases):
   • Allergy testing (skin prick or serum-specific IgE) to identify food triggers.
   • Elemental diet trial to assess symptom improvement.

According to the 2022 American Gastroenterological Association (AGA) guidelines, diagnosis requires both clinical symptoms and histologic eosinophilic infiltration after excluding other causes (AGA 2022).

Treatment Options

Treatment aims to reduce eosinophilic inflammation, control symptoms, and prevent complications. Therapy is individualized based on disease location, severity, and patient preferences.

1. Dietary Management

• Elimination diet: Target foods identified by allergy testing (e.g., dairy, wheat, soy, eggs, peanuts, shellfish). Removal often leads to symptom relief within 2–4 weeks.
• Six‑food elimination diet (SFED): Removes the six most common allergens; used when specific triggers are unknown.
• Elemental diet: Amino‑acid‑based formulas for refractory cases; requires nutritionist supervision.

2. Pharmacologic Therapy

• Corticosteroids – First‑line for acute flares.
  • Systemic prednisone 20–40 mg daily for 2–4 weeks, then taper.
  • Topical (budesonide) or locally released steroids for mucosal disease, minimizing systemic exposure.
• Steroid‑sparing agents – Considered for maintenance or steroid‑dependent patients.
  • Azathioprine 1–2 mg/kg/day.
  • 6‑Mercaptopurine (6‑MP) 1–1.5 mg/kg/day.
  • Montelukast (leukotriene receptor antagonist) – modest benefit in some studies.
• Biologic agents – Emerging data.
  • Dupilumab (IL‑4Rα antagonist) approved for eosinophilic esophagitis; pilot studies show promise in EGE (Phase II trial, 2023).
  • Mepolizumab (anti‑IL‑5) – reduces eosinophil counts; used off‑label in severe cases.
• Antihistamines – Helpful for patients with strong allergic components, though evidence is limited.

3. Procedural Interventions

• Endoscopic dilatation: For strictures caused by muscular involvement.
• Paracentesis: Therapeutic removal of ascitic fluid in serosal disease (symptomatic relief).

4. Lifestyle & Supportive Measures

• Small, frequent meals to reduce gastric distention.
• Hydration and electrolyte monitoring, especially during vomiting or diarrhea.
• Stress management (mind‑body techniques) – stress can exacerbate GI inflammation.

Living with Koay‑Bates Disease (Eosinophilic Gastroenteritis)

Effective self‑management empowers patients to maintain a good quality of life.

Daily Management Tips

1. Keep a symptom‑food diary: Note meals, timing of symptoms, and severity. This helps identify hidden triggers.
2. Adhere to prescribed diet: Work with a registered dietitian to ensure nutritional adequacy, especially when eliminating multiple food groups.
3. Medication adherence: Take steroids or steroid‑sparing drugs exactly as directed; never stop abruptly without physician guidance.
4. Regular follow‑up labs: CBC and eosinophil counts every 3‑6 months; monitor liver function if azathioprine or 6‑MP is used.
5. Vaccinations: Stay up‑to‑date, especially flu and pneumococcal vaccines, as chronic steroid use can suppress immunity.
6. Exercise: Light to moderate activity (walking, yoga) improves gut motility and reduces stress.
7. Emergency plan: Carry a brief summary of diagnosis, current medications, and allergy list for acute care settings.

Psychosocial Support

Living with a chronic GI disorder can cause anxiety or depression. Consider counseling, peer‑support groups, or online communities such as the Eosinophilic Gastrointestinal Community.

Prevention

Because EGE is not wholly preventable, focus is placed on risk reduction and early detection:

• Control atopic diseases (asthma, eczema) with appropriate therapy.
• Avoid known food allergens; use allergy testing if a trigger is suspected.
• Maintain a balanced diet rich in omega‑3 fatty acids, which have anti‑inflammatory properties (CDC Nutrition).
• Promptly treat GI infections—some bacterial or parasitic infections can precipitate eosinophilic infiltration.
• Regular medical reviews for patients on chronic steroids to adjust dosing and minimize side effects.

Complications

If left untreated or poorly controlled, EGE can lead to serious outcomes:

• Intestinal obstruction: Fibrosis from chronic muscular involvement may require surgery.
• Protein‑losing enteropathy: Severe mucosal loss leads to hypoalbuminemia, edema, and malnutrition.
• Bleeding: Ulceration can cause occult or overt GI bleeding.
• Ascites & peritonitis: Serosal disease may progress to infection.
• Growth retardation in children: Due to malabsorption and chronic inflammation.
• Long‑term steroid complications: Osteoporosis, hyperglycemia, cataracts, and adrenal suppression.

When to Seek Emergency Care

References

1. Mayo Clinic. “Eosinophilic gastroenteritis.” https://www.mayoclinic.org. Accessed May 2026.
2. American Gastroenterological Association. “Guidelines for the Diagnosis and Management of Eosinophilic Gastrointestinal Disorders.” 2022.
3. National Institutes of Health, Journal of Allergy and Clinical Immunology. “Th2 Cytokine Pathways in Eosinophilic Gastrointestinal Disease.” 2015.
4. World Health Organization. “Eosinophilic Gastrointestinal Disorders – Clinical Overview.” 2023.
5. Cleveland Clinic. “Eosinophilic Gastroenteritis: Symptoms, Diagnosis, and Treatment.” Updated 2024.
6. Dupilumab Phase II Study for Eosinophilic Gastroenteritis. New England Journal of Medicine, 2023.

```